L

LTR Pharma Ltd
ASX:LTP

Watchlist Manager
LTR Pharma Ltd
ASX:LTP
Watchlist
Price: 0.73 AUD -3.95%
Market Cap: 112.3m AUD
Have any thoughts about
LTR Pharma Ltd?
Write Note

Relative Value

The Relative Value of one LTP stock under the Base Case scenario is 0.01 AUD. Compared to the current market price of 0.73 AUD, LTR Pharma Ltd is Overvalued by 99%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LTP Relative Value
Base Case
0.01 AUD
Overvaluation 99%
Relative Value
Price
L
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
15
vs Industry
Median 3Y
2 077.1
Median 5Y
2 077.1
Industry
2.5
vs History
vs Industry
Median 3Y
-25.3
Median 5Y
-25.3
Industry
21.4
vs History
vs Industry
Median 3Y
-26.3
Median 5Y
-26.3
Industry
16
vs History
vs Industry
Median 3Y
-26.3
Median 5Y
-26.3
Industry
23.3
vs History
15
vs Industry
3
Median 3Y
37.7
Median 5Y
37.7
Industry
2.1
vs History
15
vs Industry
Median 3Y
2 070.7
Median 5Y
2 070.7
Industry
2.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.1
vs History
vs Industry
Median 3Y
-24.4
Median 5Y
-24.4
Industry
13.7
vs History
vs Industry
Median 3Y
-24.4
Median 5Y
-24.4
Industry
16.7
vs History
vs Industry
Median 3Y
-22.9
Median 5Y
-22.9
Industry
15.1
vs History
vs Industry
Median 3Y
-22.9
Median 5Y
-22.9
Industry
18.9
vs History
15
vs Industry
0
Median 3Y
4 153.2
Median 5Y
4 153.2
Industry
1.9

Multiples Across Competitors

LTP Competitors Multiples
LTR Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
LTR Pharma Ltd
ASX:LTP
104.6m AUD 2 077.1 -14.6 -16.7 -16.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
747.7B USD 18.3 89.3 48 53.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK 10.3 29.4 20.4 23.3
US
Johnson & Johnson
NYSE:JNJ
342.5B USD 3.9 23.3 11.3 14.7
US
Merck & Co Inc
NYSE:MRK
252.8B USD 4 20.8 10.5 12.6
CH
Roche Holding AG
SIX:ROG
216.7B CHF 3.7 18.8 10.6 12.5
UK
AstraZeneca PLC
LSE:AZN
170.2B GBP 4.3 32.5 169.2 253.5
CH
Novartis AG
SIX:NOVN
179.3B CHF 3.9 11.2 9.7 13.5
US
Pfizer Inc
NYSE:PFE
152.2B USD 2.5 35.8 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
AU
L
LTR Pharma Ltd
ASX:LTP
Average P/S: 383 130.8
2 077.1
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
7%
601 676.1
US
Eli Lilly and Co
NYSE:LLY
18.3
28%
0.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
9%
64.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
21%
0.5
US
Johnson & Johnson
NYSE:JNJ
3.9
4%
1
US
Merck & Co Inc
NYSE:MRK
4
6%
0.7
CH
Roche Holding AG
SIX:ROG
3.7
5%
0.7
UK
AstraZeneca PLC
LSE:AZN
4.3
10%
0.4
CH
Novartis AG
SIX:NOVN
3.9
6%
0.7
US
Pfizer Inc
NYSE:PFE
2.5
3%
0.8
P/E Multiple
Earnings Growth PEG
AU
L
LTR Pharma Ltd
ASX:LTP
Average P/E: 32.6
Negative Multiple: -14.6
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
89.3
76%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29.4
23%
1.3
US
Johnson & Johnson
NYSE:JNJ
23.3
-8%
N/A
US
Merck & Co Inc
NYSE:MRK
20.8
320%
0.1
CH
Roche Holding AG
SIX:ROG
18.8
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
32.5
40%
0.8
CH
Novartis AG
SIX:NOVN
11.2
9%
1.2
US
Pfizer Inc
NYSE:PFE
35.8
102%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
L
LTR Pharma Ltd
ASX:LTP
Average EV/EBITDA: 459.6
Negative Multiple: -16.7
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48
42%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
20.4
22%
0.9
US
Johnson & Johnson
NYSE:JNJ
11.3
4%
2.8
US
Merck & Co Inc
NYSE:MRK
10.5
63%
0.2
CH
Roche Holding AG
SIX:ROG
10.6
7%
1.5
UK
AstraZeneca PLC
LSE:AZN
169.2
18%
9.4
CH
Novartis AG
SIX:NOVN
9.7
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.6
9%
1.2
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
L
LTR Pharma Ltd
ASX:LTP
Average EV/EBIT: 2 011.3
Negative Multiple: -16.7
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.6
45%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
23.3
22%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.7
9%
1.6
US
Merck & Co Inc
NYSE:MRK
12.6
98%
0.1
CH
Roche Holding AG
SIX:ROG
12.5
9%
1.4
UK
AstraZeneca PLC
LSE:AZN
253.5
32%
7.9
CH
Novartis AG
SIX:NOVN
13.5
17%
0.8
US
Pfizer Inc
NYSE:PFE
16
19%
0.8